Important Pharmacogenetic Information for Drugs Prescribed During the SARS‐CoV‐2 Infection (COVID‐19)

In December 2019, the severe acute respiratory syndrome virus‐2 pandemic began, causing the coronavirus disease 2019. A vast variety of drugs is being used off‐label as potential therapies. Many of the repurposed drugs have clinical pharmacogenetic guidelines available with therapeutic recommendatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Zubiaur, Pablo, Koller, Dora, Saiz‐Rodríguez, Miriam, Navares‐Gómez, Marcos, Abad‐Santos, Francisco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7719396/
https://www.ncbi.nlm.nih.gov/pubmed/32936528
http://dx.doi.org/10.1111/cts.12866
Descripción
Sumario:In December 2019, the severe acute respiratory syndrome virus‐2 pandemic began, causing the coronavirus disease 2019. A vast variety of drugs is being used off‐label as potential therapies. Many of the repurposed drugs have clinical pharmacogenetic guidelines available with therapeutic recommendations when prescribed as indicated on the drug label. The aim of this review is to provide a comprehensive summary of pharmacogenetic biomarkers available for these drugs, which may help to prescribe them more safely.

Ejemplares similares